---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005457"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T03:05:21.857929+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex Q2 net loss $0.77/sh; barzolvolimab Ph2 studies initiated; settles SRS litigation

## Summary
- Net loss $36M ($0.77/sh) vs $13.4M ($0.34/sh) in Q2 2021; revenue $0.2M down from $3.5M.
- Cash $356.8M at June 30; management says sufficient through 2025.
- Barzolvolimab interim CSU: mean UAS7 reduction 66.6% (1.5mg/kg) and 75.1% (3mg/kg); Phase 2 studies dosed.
- Settled Kolltan contingent milestones reduced from $172.5M to $80M; $15M paid in July; $6.3M remeasurement gain.
- Deprioritized CDX-1140 program; focusing on barzolvolimab and bispecific platform.

## SEC filing metadata
- accession: 0001171843-22-005457
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/0001171843-22-005457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/f8k_080822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005457
- JSON: https://secwatch.observer/filing/0001171843-22-005457.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.